EA201890524A1 - (s,e)-3-(6-аминопиридин-3-ил)-n-((5-(4-(3-фтор-3-метилпирролидин-1-карбонил)фенил)-7-(4-фторфенил)бензофуран-2-ил)метил)акриламид для лечения рака - Google Patents

(s,e)-3-(6-аминопиридин-3-ил)-n-((5-(4-(3-фтор-3-метилпирролидин-1-карбонил)фенил)-7-(4-фторфенил)бензофуран-2-ил)метил)акриламид для лечения рака

Info

Publication number
EA201890524A1
EA201890524A1 EA201890524A EA201890524A EA201890524A1 EA 201890524 A1 EA201890524 A1 EA 201890524A1 EA 201890524 A EA201890524 A EA 201890524A EA 201890524 A EA201890524 A EA 201890524A EA 201890524 A1 EA201890524 A1 EA 201890524A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fluoro
phenyl
pharmaceutically acceptable
acceptable salt
compound
Prior art date
Application number
EA201890524A
Other languages
English (en)
Russian (ru)
Inventor
Эркан Балоглу
Шэрон Шачам
Уильям Сенапедис
Original Assignee
Кариофарм Терапевтикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кариофарм Терапевтикс Инк. filed Critical Кариофарм Терапевтикс Инк.
Publication of EA201890524A1 publication Critical patent/EA201890524A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA201890524A 2015-08-18 2016-08-18 (s,e)-3-(6-аминопиридин-3-ил)-n-((5-(4-(3-фтор-3-метилпирролидин-1-карбонил)фенил)-7-(4-фторфенил)бензофуран-2-ил)метил)акриламид для лечения рака EA201890524A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206472P 2015-08-18 2015-08-18
PCT/US2016/047566 WO2017031323A1 (en) 2015-08-18 2016-08-18 (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer

Publications (1)

Publication Number Publication Date
EA201890524A1 true EA201890524A1 (ru) 2018-07-31

Family

ID=56799634

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890524A EA201890524A1 (ru) 2015-08-18 2016-08-18 (s,e)-3-(6-аминопиридин-3-ил)-n-((5-(4-(3-фтор-3-метилпирролидин-1-карбонил)фенил)-7-(4-фторфенил)бензофуран-2-ил)метил)акриламид для лечения рака

Country Status (12)

Country Link
US (1) US10363247B2 (cg-RX-API-DMAC10.html)
EP (1) EP3337797A1 (cg-RX-API-DMAC10.html)
JP (1) JP2018528196A (cg-RX-API-DMAC10.html)
CN (1) CN108137563A (cg-RX-API-DMAC10.html)
AU (1) AU2016308829A1 (cg-RX-API-DMAC10.html)
CA (1) CA2995380A1 (cg-RX-API-DMAC10.html)
EA (1) EA201890524A1 (cg-RX-API-DMAC10.html)
HK (1) HK1255438A1 (cg-RX-API-DMAC10.html)
IL (1) IL257422A (cg-RX-API-DMAC10.html)
MA (1) MA42655A (cg-RX-API-DMAC10.html)
MX (1) MX2018001979A (cg-RX-API-DMAC10.html)
WO (1) WO2017031323A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6397010B2 (ja) 2013-07-03 2018-09-26 カリオファーム セラピューティクス,インコーポレイテッド 置換されたベンゾフラニル及びベンゾオキサゾリル化合物並びにその使用
WO2015042414A1 (en) 2013-09-20 2015-03-26 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
WO2017031323A1 (en) 2015-08-18 2017-02-23 Karyopharm Therapeutics Inc. (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer
US10858347B2 (en) 2015-12-31 2020-12-08 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
CN111171233B (zh) * 2020-01-17 2023-03-31 吉林师范大学 一种新型磁性薄层印迹膜的制备方法及用途
JP7706169B2 (ja) * 2020-02-26 2025-07-11 上海科技大学 抗コロナウイルスにおけるジスルフィラムの使用
CN114507215B (zh) * 2020-11-14 2024-09-13 成都海博为药业有限公司 一种作为pak4激酶抑制剂的化合物及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
DE19818044A1 (de) 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Verwendung von Vitamin-PP-Verbindungen
JP2004534857A (ja) 2001-07-19 2004-11-18 フアルマシア・イタリア・エツセ・ピー・アー フェニルアセトアミド−チアゾール誘導体、それらの製造のための方法及び抗癌剤としてのそれらの使用
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
WO2004106317A1 (ja) 2003-05-29 2004-12-09 The New Industry Research Organization ベンゾフラン化合物、およびそれを含有してなる医薬組成物
JP4709757B2 (ja) 2003-08-07 2011-06-22 ニツポネツクス・インコーポレーテツド 過剰増殖性障害の処置に有用なベンゾフラン誘導体
US7368476B2 (en) 2004-04-07 2008-05-06 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
EP2261218B1 (en) 2004-05-26 2013-04-03 Eisai R&D Management Co., Ltd. Imidazole compound for use as an intermediate in the production of cinnamide compounds
WO2006038606A1 (ja) 2004-10-05 2006-04-13 Shionogi & Co., Ltd. ビアリール誘導体
US8084492B2 (en) 2004-11-19 2011-12-27 The New Industry Research Organization Benzofuran compound and pharmaceutical composition containing the same
BRPI0608659A2 (pt) 2005-04-06 2010-11-30 Astrazeneca Ab composto, métodos para limitar a proliferação celular, de tratamento de um ser humano ou animal sofrendo de uma doença, e de tratamento de profilaxia do cáncer, para tratar cáncer, de tratamento de infecções associadas com cáncer, e de profilaxia de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir chk1 cinase, e um pak cinase, e para limitar a tumorigênese em um ser humano ou animal, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
JP2008538571A (ja) 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
US20080020413A1 (en) 2006-03-29 2008-01-24 Columbia University Crystalline visfatin and methods therefor
WO2008026018A1 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
EP2197443A4 (en) 2007-09-26 2014-01-01 Gemin X Pharmaceuticals Canada Inc COMPOSITIONS AND METHOD FOR LEADING NAD + MIRRORS USING A NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE HEMMER
US8173677B2 (en) 2007-09-26 2012-05-08 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
FR2943669B1 (fr) 2009-03-24 2011-05-06 Sanofi Aventis Derives de nicotinamide,leur preparation et leur application en therapeutique
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
BR112012021806A2 (pt) 2010-03-01 2015-09-08 Myrexis Inc compostos e seus usos terapêusticos.
US20130317027A1 (en) 2010-03-01 2013-11-28 Myrexis, Inc. Compounds and therapeutic uses thereof
JP5978293B2 (ja) 2011-05-04 2016-08-24 フォーマ ティーエム, エルエルシー. Namptを阻害するための新規な化合物および組成物
EP2739144A4 (en) 2011-06-20 2015-04-01 Alzheimer S Inst Of America Inc COMPOUNDS AND ITS THERAPEUTIC USE
WO2013082150A1 (en) 2011-11-30 2013-06-06 The Curators Of The University Of Missouri Small molecule inhibitors of nicotinamide phosphoribosyltransferase (nampt)
WO2014074715A1 (en) 2012-11-07 2014-05-15 Genentech, Inc. Cyclopropyl amide derivatives
EP2925750A1 (en) * 2012-11-29 2015-10-07 Karyopharm Therapeutics, Inc. Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
JP6397010B2 (ja) * 2013-07-03 2018-09-26 カリオファーム セラピューティクス,インコーポレイテッド 置換されたベンゾフラニル及びベンゾオキサゾリル化合物並びにその使用
WO2015042414A1 (en) 2013-09-20 2015-03-26 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
WO2015054060A1 (en) 2013-10-09 2015-04-16 Eli Lilly And Company Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors
WO2016100515A1 (en) 2014-12-16 2016-06-23 Karyopharm Therapeutics Inc. Cyclic compounds and uses thereof
WO2017031213A1 (en) 2015-08-17 2017-02-23 Karyopharm Therapeutics Inc. 3-(pyridin-3-yl)-acrylamide and n-(pyridin-3-yl)-acrylamide derivatives and their use as pak or nampt modulators
WO2017031204A1 (en) 2015-08-17 2017-02-23 Karyopharm Therapeutics Inc. Cyclopropylderivatives and their use as kinase inhibitors
WO2017031323A1 (en) 2015-08-18 2017-02-23 Karyopharm Therapeutics Inc. (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer
US10858347B2 (en) 2015-12-31 2020-12-08 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
US20190002448A1 (en) 2015-12-31 2019-01-03 Karyopharm Therapeutics Inc. Substituted benzofuranyl and benzoxazolyl compounds and uses thereof

Also Published As

Publication number Publication date
AU2016308829A1 (en) 2018-03-08
MX2018001979A (es) 2019-04-25
JP2018528196A (ja) 2018-09-27
US10363247B2 (en) 2019-07-30
CN108137563A (zh) 2018-06-08
WO2017031323A1 (en) 2017-02-23
MA42655A (fr) 2021-04-07
US20180235948A1 (en) 2018-08-23
IL257422A (en) 2018-04-30
HK1255438A1 (zh) 2019-08-16
EP3337797A1 (en) 2018-06-27
CA2995380A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
EA201890338A1 (ru) Оксадиазольные производные, пригодные в качестве ингибиторов hdac
EA201991515A1 (ru) N-[4-фтор-5-[[(2s,4s)-2-метил-4-[(5-метил-1,2,4-оксадиазол-3-ил)метокси]-1-пиперидил]метил]тиазол-2-ил]ацетамид в качестве ингибитора oga
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
EA201691853A1 (ru) Агонисты мускариновых рецепторов
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
MX2018001979A (es) (s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer.
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
EA201790476A1 (ru) Аминопиридилоксипиразольные соединения
EA201491012A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
EA201690752A1 (ru) Ингибиторы g12c kras
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
EA201590975A1 (ru) Ингибиторы prmt5 и их применение
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
EA201590228A1 (ru) Антагонисты 5-ht3 рецептора
EA201400161A1 (ru) Замещенные гетероароматические пиразолсодержащие карбоксамидные и мочевинные производные в качестве лигандов ваниллоидных рецепторов
EA201790088A1 (ru) Ингибиторы syk
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
MA35716B1 (fr) Formulations pharmaceutiques
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2